714 related articles for article (PubMed ID: 24322792)
1. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
2. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
3. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
5. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
[TBL] [Abstract][Full Text] [Related]
6. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
[TBL] [Abstract][Full Text] [Related]
7. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
[TBL] [Abstract][Full Text] [Related]
8. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
Du Y; Cullum I; Illidge TM; Ell PJ
J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
10. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
11. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
[TBL] [Abstract][Full Text] [Related]
12. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.
Kruse V; Van de Wiele C; Borms M; Maes A; Pottel H; Sathekge M; Cocquyt V
Nuklearmedizin; 2014 Aug; 53(4):131-8. PubMed ID: 25100557
[TBL] [Abstract][Full Text] [Related]
13. The pivotal role of FDG-PET/CT in modern medicine.
Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
[TBL] [Abstract][Full Text] [Related]
14. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
15. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA
Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study.
Grassetto G; Fornasiero A; Otello D; Bonciarelli G; Rossi E; Nashimben O; Minicozzi AM; Crepaldi G; Pasini F; Facci E; Mandoliti G; Marzola MC; Al-Nahhas A; Rubello D
Eur J Radiol; 2011 Dec; 80(3):828-33. PubMed ID: 20547020
[TBL] [Abstract][Full Text] [Related]
19. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
20. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]